Methylphenidate. An update on extended-release formulations

Methylphenidate remains the mainstay of pharmacological management in attention deficit hyperactivity disorder [ADHD]. Despite having been available for over half a century, methylphenidate's original formulation has been modified with the main purpose of extending its duration of action. This article will present a brief review of how these new formulations vary and how these should be selected, considering the evidence available on their effectiveness and on the individual needs of the patient

Long-acting injectable antipsychotics Review and recent developments

Long-acting injectable antipsychotics, also known as "depots", were developed in the late 1960s as an attempt to improve compliance and long-term management of schizophrenia. Despite their availability for over 30 years, guidelines for their use and data on patients for whom long-acting injectable antipsychotics are most indicated are sparse and vary considerably. A review of the perceived advantages and disadvantages of using long-acting injectable antipsychotics is provided in this article, as well as a review of the literature to update clinicians on the current advances of this therapeutic option to optimize compliance and long-term management of chronic schizophrenia